Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases

Inclusion Criteria * Patient with biopsy-proven primary stage I-III infiltrating adenocarcinoma of the breast. * HER-2/neu (+) as determined by either IHC (3+) or FISH (≥ 2.2-fold amplification). * Age ≥ 18 years. * ECOG performance status 0-1. * Negative CT C/A/P and TBBS. * LVEF \> 50% by MUGA or echocardiogram performed within 28 days prior to enrollment * Positive BM aspirate for BC micrometastases by CLIA-certified laboratory. * Adequate hematologic, hepatic, and renal function. All tests must be obtained ≤ 4 weeks prior to randomization. * Hematologic: Absolute neutrophil count \> 1,500/mm3 Hemoglobin \> 10.0 g/dl Platelet count \> 100,000/mm3. * Hepatic: Total bilirubin must be within normal limits. Transaminases (AST and/or ALT) may be \< 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is \< ULN, or alkaline phosphatase may be \< 4 x ULN if transaminases are \< ULN * Renal: Normal creatinine and BUN; if abnormal, calculated creatinine clearance must be\> 60 mg/dL * Patients must be disease-free of prior invasive malignancies for ≥ 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * Surgery: all patients must have completed surgery with sentinel and/or axillary lymph node dissection according to participating institutional guidelines. * Women of childbearing potential must have a negative pregnancy test and must be willing to consent to using an accepted and effective barrier form method of contraception while on treatment and for a reasonable period thereafter. * Patients must provide written informed consent. * Note: Hormonal therapy: patients with ER+ and/or PR+ tumors may receive concurrent hormonal therapy according to participating institutional guidelines. The choice of hormonal therapy is at the discretion of the treating physician. * Note: Radiation therapy: patients receiving adjuvant radiation therapy to the involved breast (after partial mastectomy) or chest wall (after mastectomy) may receive concurrent trastuzumab and bevacizumab therapy. Exclusion Criteria * Known metastatic BC. * Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. * Pregnant or lactating women. * Prior chemotherapy, hormonal therapy, trastuzumab and bevacizumab therapy. * History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias * Ejection fraction \<50% or below the lower limit of the institutional normal range, whichever is lower. * Hypersensitivity to trial medications. * Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest. * Active or uncontrolled infection. * Psychiatric, addictive, or any disorder that compromises the ability to give informed consent to participate in or to comply with the requirements of the study. Bevacizumab-Specific Exclusions * Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications) * Any prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure * History of stroke or transient ischemic attack within 6 months prior to study enrollment * Known CNS disease * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment * Serious, non-healing wound, ulcer, or bone fracture * Proteinuria at screening as demonstrated by either * Urine protein:creatinine (UPC) ratio \>/= 1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab * Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential * History of stroke or transient ischemic attack at any time * History of myocardial infarction or unstable angina within 12 months of study enrollment